“We are excited and honored to be recognized by our customers and the users of our eCOA solutions,” said Ron Sullivan, Executive Vice President, eCOA, ERT
July 23, 2015 (PRWEB) July 23, 2015 -- ERT, a leading global provider of high-quality patient safety and efficacy endpoint data collection, cloud analytics and workflow solutions, today announced it was ranked highest among electronic Clinical Outcome Assessment (eCOA) providers in overall satisfaction in an independent report issued by Industry Standard Research® (ISR).The report “EDC and eCOA / ePRO Market Dynamics and Service Provider Performance (2015)” captures data from over 150 global industry professionals representing pharmaceutical companies, CROs, and clinical research sites who have direct experience working with eCOA / ePRO technology.
The report shows that ERT was rated highest among 22 eCOA / ePRO providers in Overall Satisfaction, Usability, System Flexibility & Support, and Validation & Patient Compliance. ERT’s highest ratings in these categories were derived from questions pertaining to scientific consulting / expertise, study set-up time, and solutions that ensure good patient protocol compliance.The report also shows a strong and growing preference in the industry for eCOA / ePRO (76%) over traditional paper diaries, as compared to 61% noted in the 2013 ISR report.
“We are excited and honored to be recognized by our customers and the users of our eCOA solutions,” said Ron Sullivan, Executive Vice President, eCOA, ERT. “Customer satisfaction is our number one priority and the ultimate barometer of success. To be rated as the highest eCOA / ePRO provider for overall satisfaction is a testament to our employees’ commitment to exceeding customer expectations and to our collective focus on the flexibility and usability of our products and services.”
Andrew Schafer, President of ISR Reports commented, "We believe that the pharmaceutical industry needs a different, higher quality source of market research. Our endeavor has been to fill that need. The data for "EDC and eCOA / ePRO Market Dynamics and Service Provider Performance (2015)" were collected in Q1, 2015 and, as with all our research, we have adhered to the highest standards of quality and integrity in generating this report. We are hopeful that it provides necessary insights to our customers and enables their strategic business decisions."
Learn more about ERT’s eCOA solutions and services at http://www.ert.com/eCOA/.
ERT (http://www.ert.com) is a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process throughout the product lifecycle. ERT delivers the most widely deployed solutions in centralized Cardiac Safety, Respiratory, Suicide Risk Assessment, electronic Clinical Outcome Assessments (eCOA) – which includes patient-, clinician-, observer- and performance-reported outcomes – and cloud-based analytics and performance metrics. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes and delivers safety and efficacy data critical to the approval, labeling and reimbursement of pharmaceutical products. ERT is a global organization with headquarters in Philadelphia, PA and offices throughout the U.S., U.K., Switzerland, Japan and Germany.
About ISR Reports
Industry Standard Research (ISR) is a full service pharmaceutical market research and consulting company servicing the pharmaceutical and biopharmaceutical services industries. ISR combines domain expertise with unmatched market research rigor. Its' clients include nearly all of the global pharmaceutical service providers and a vast majority of the top 30 biopharmaceutical companies. ISR's syndicated reports offer novel, strategic insight into important industry topics and have practical applications across the pharmaceutical and pharmaceutical services industry.